| II-49 Sylvaine Galiegue Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies Wednesday 15:35-17:00 |
| II-49 Sylvaine Galiegue Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies Wednesday 15:35-17:00 |